|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that high ERBB3 gene expression correlates with decreased survival in the intestinal type of gastric cancer.
|
30726523 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ErbB1 and ErbB3 expressions were analyzed by immunohistochemistry and real-time PCR in 50 patients with gastric cancer.
|
30621788 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Resistance is reverted by simultaneous inhibition of EGFR, HER2, and HER3, thereby revealing a potential therapeutic strategy to overcome trastuzumab resistance in patients with gastric cancer.
|
31484705 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated prevalence of Her3 in gastric cancer, in a Saudi cohort of cases, along with its association with prognostic markers p53 and Ki-67.
|
30915908 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
NRG1 overexpression was observed in 141 (28.1%) GCs and closely correlated with HER3 (P = 0.034) and HER4 (P < 0.001) expression.
|
28573357 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Besides, SNP rs3202538 (G/T) in ErbB3 3'-UTR was involved in the occurrence of GC by acting as tumor risk factors.
|
28924391 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the expression levels of various ERBB receptor ligands (i.e., heparin-binding epidermal growth factor-like growth factor [HBEGF], transforming growth factor-α [TGFA], amphiregulin [AREG], epiregulin [EREG], epidermal growth factor [EGF], and betacellulin [BTC]) and 3 ERBB family receptors (i.e., epidermal growth factor receptor [EGFR], human EGFR2 [HER2], and ERBB3) in 313 cases of GC using immunohistochemistry, fluorescence in situ hybridization, and mRNA in situ hybridization.
|
28399526 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the prognostic value of HER2-HER3 overexpression remains unknown in gastric cancer (GC).
|
29233126 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
28899363 |
2017 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, we identified EHF as a new HER2 transcription factor and the modulator of HER3 and HER4 in gastric cancer.
|
27787520 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings offer compelling evidence that APIP plays an essential role in ERBB3 signaling as a positive regulator for tumorigenesis, warranting future development of therapeutic strategies for ERBB3-driven gastric cancer.
|
26942872 |
2016 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, various molecular transduction patterns: Her2/Her3 and Met/Her3 were verified in human GC, and Her3 could serve as a potential target in GC treatment.
|
25400108 |
2015 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the data suggest that ERBB3 is altered in GC and CRC by various ways, including somatic mutations and increased expression that might play roles in tumorigenesis.
|
24909266 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, of the RTKs studied, HER3 was the only RTK identified as an independent prognostic indicator of stage II/III advanced gastric cancer with standard treatment.
|
25455899 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we report the identification of ERBB3 somatic mutations in ~11% of colon and gastric cancers.
|
23680147 |
2013 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nuclear YB-1 expression was significantly (P = 0.026) associated with HER2 expression, but not with EGFR or HER3, in patients with gastric cancer (n = 111).
|
23445612 |
2013 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
ErbB3 was found to be phosphorylated selectively in dedifferentiated adenocarcinoma cell lines among various gastric cancer cell lines.
|
12618754 |
2003 |
|
Malignant neoplasm of stomach
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|